What's Happening?
The U.S. Food and Drug Administration (FDA) is actively revisiting its categorization of peptide substances under Section 503A of the Federal Food, Drug, and Cosmetic Act. This section allows state-licensed pharmacies and physicians to compound drugs
without new-drug approval, provided certain conditions are met. The FDA is evaluating which peptides should be included on the 503A bulks list, which affects their legal status for compounding. Recently, the FDA removed 12 peptides from Category 2, which flags substances as significant safety risks, but has not yet placed them in Category 1, which allows for enforcement discretion. The Pharmacy Compounding Advisory Committee (PCAC) will review several peptides in upcoming meetings, but their recommendations are non-binding.
Why It's Important?
The FDA's decisions on peptide categorization have significant implications for compounding pharmacies, telehealth platforms, and manufacturers. The placement of peptides in different categories affects whether they can be compounded legally, impacting the availability of these substances for medical use. The ongoing review process creates uncertainty for stakeholders who rely on these substances for patient care. Additionally, the FDA's scrutiny of advertising practices related to peptides highlights the need for companies to ensure compliance with regulatory standards to avoid enforcement actions.
What's Next?
The FDA's upcoming PCAC meetings will consider the status of several peptides, but even favorable recommendations will not result in immediate authorization. The FDA must complete formal rulemaking before adding substances to the bulks list, a process that can take over a year. Companies involved in peptide compounding should prepare for potential regulatory changes and ensure their advertising practices comply with FDA guidelines. Stakeholders are encouraged to participate in the public comment process to influence the FDA's decisions.
